Tech Company Financing Transactions
Teva Pharmaceutical Industries Funding Round
On 3/3/2026, Teva Pharmaceutical Industries received $400 million in funding from Blackstone.
Transaction Overview
Company Name
Announced On
3/3/2026
Transaction Type
Venture Equity
Amount
$400,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5 Basel St.
Petach Tikva, 49131
Israel
Petach Tikva, 49131
Israel
Phone
Website
Email Address
Overview
Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) engages in the development, manufacture, and marketing of generic and human pharmaceuticals, active pharmaceutical ingredients (APIs), and animal health pharmaceutical products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kåre Schultz
Chief Financial Officer
Michael McClellan
Executive Vice President
Richard Daniell
VP - Bus. Development
Gianfranco Nazzi
VP - Marketing
Iris Beck-Codner
VP - Marketing
Sven Dethlefs
VP - R & D
Hafrun Fridriksdottir
Browse more venture capital transactions:
Prev: 3/3/2026: Wereldhave venture capital transaction
Next: 3/3/2026: Delphyr venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs